Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic ...
Veeva Systems VEEV has shown strong momentum during fiscal 2026 across its commercial and R&D businesses, supported by rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results